Liposeuticals

LipoSeuticals is a specialty pharmaceuticals company founded in 2012, dedicated to pioneering advanced formulations for sterile injectable drugs with a focus on anesthesiology, oncology, and infectious disease. The company has developed a unique method for formulating non-water-soluble drugs, resulting in improved stability, longer shelf life, easier manufacturing processes, and increased safety. Specifically designed for development through the 505(b)(2) pathway at the United States Food and Drug Administration (FDA), their pipeline aims to expedite the development, review, and approval process. Additionally, LipoSeuticals seeks to extend the market longevity of its products by creating new intellectual property and leveraging regulatory exclusivity provided by the Hatch-Waxman Act. The last notable investment in LipoSeuticals was a Series A investment on 29 June 2017 led by Delos Capital. The company operates in the Biotechnology, Health Care, and Pharmaceutical sectors, aiming to bring significant advancements to the healthcare industry through their innovative drug formulations. With a strong focus on improving drug stability and safety, LipoSeuticals presents an intriguing prospect for venture capital looking to invest in cutting-edge solutions within the pharmaceutical space.

Overall, LipoSeuticals presents a compelling opportunity for investors as it continues to pioneer advanced drug formulations aimed at enhancing the efficacy and safety of sterile injectable drugs within critical medical fields. With a solid foundation and backing from notable investors such as Delos Capital, the company is well-positioned to drive innovation and make a significant impact in the biopharmaceutical industry.